BioLife Solutions Files 8-K on Financial Condition

TL;DR

**BLFS filed an 8-K on financial results, expect new info soon.**

AI Summary

BioLife Solutions, Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition.' This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. While specific financial figures are not detailed in this particular excerpt, the filing itself signals that new financial information is being disclosed, which could impact investor sentiment and stock valuation.

Why It Matters

This filing signals that BioLife Solutions is updating the market on its financial performance, which is critical for investors to assess the company's health and make informed decisions about buying, holding, or selling its stock.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition, not indicating any immediate adverse events or significant changes in risk.

Analyst Insight

Investors should look for the full content of the 'Results of Operations and Financial Condition' to understand the specific financial updates and their potential impact on BioLife Solutions, Inc.'s stock price.

Key Numbers

• 001-36362 — Commission File Number (identifies BioLife Solutions, Inc. with the SEC)
• 94-3076866 — IRS Employer Identification No. (identifies BioLife Solutions, Inc. for tax purposes)
• 425-402-1400 — Registrant's telephone number (contact information for BioLife Solutions, Inc.)

Key Players & Entities

• BioLife Solutions, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for BioLife Solutions, Inc.
• The NASDAQ Stock Market LLC (company) — exchange where BioLife Solutions, Inc. Common Stock is registered
• BLFS (company) — trading symbol for BioLife Solutions, Inc.
• January 8, 2024 (date) — date of earliest event reported and filing date
• $0.001 (dollar_amount) — par value per share of Common Stock

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BLFS The NASDAQ Stock Market

Filing Documents

• blfs-20240108.htm (8-K) — 25KB
• a991-q42023preliminaryreve.htm (EX-99.1) — 18KB
• imagea.jpg (GRAPHIC) — 77KB
• 0001628280-24-000776.txt ( ) — 275KB
• blfs-20240108.xsd (EX-101.SCH) — 2KB
• blfs-20240108_lab.xml (EX-101.LAB) — 23KB
• blfs-20240108_pre.xml (EX-101.PRE) — 12KB
• blfs-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, the BioLife Solutions, Inc. (the "Company") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of BioLife Solutions, Inc., dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioLife Solutions, Inc. Date: January 8, 2024 By: /s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR